checkAd

BioCryst Announces Approval of ORLADEYO (berotralstat) by the Israeli Ministry of Health

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.

“We continue to make significant progress in bringing our oral, once-daily prophylactic therapy to many HAE patients around the world,” said Charlie Gayer, chief commercial officer of BioCryst. “With today’s announcement, we look forward to working with our partner Neopharm to launch ORLADEYO in Israel.”

“The approval of ORLADEYO is a major advancement for the HAE community in Israel. We are proud to partner with BioCryst to bring this oral therapy to patients who are in search of a less burdensome treatment option to help manage their disease,” said Efi Shnaidman, general manager of Neopharm Israel.

Neopharm Group has the exclusive rights to commercialize ORLADEYO in Israel.

ORLADEYO was safe and well tolerated in clinical trials. The most frequently reported adverse reactions in patients receiving ORLADEYO compared with placebo were back pain and gastrointestinal reactions. The gastrointestinal reactions generally occurred early after initiation of treatment with ORLADEYO, became less frequent with time and typically self-resolved.

About ORLADEYO (berotralstat)
ORLADEYO (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

U.S. Indication and Important Safety Information

INDICATION
ORLADEYO (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION

An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

Seite 1 von 4



0 Kommentare
Nachrichtenquelle: globenewswire
 |  105   |   |   

Schreibe Deinen Kommentar

Disclaimer

BioCryst Announces Approval of ORLADEYO (berotralstat) by the Israeli Ministry of Health RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to …

Nachrichten des Autors

216 Leser
196 Leser
188 Leser
188 Leser
180 Leser
180 Leser
176 Leser
176 Leser
176 Leser
172 Leser
4372 Leser
640 Leser
584 Leser
508 Leser
504 Leser
468 Leser
468 Leser
456 Leser
448 Leser
424 Leser
4372 Leser
1688 Leser
1172 Leser
1136 Leser
956 Leser
840 Leser
828 Leser
820 Leser
820 Leser
812 Leser
10593 Leser
4428 Leser
4372 Leser
3488 Leser
2744 Leser
2294 Leser
2246 Leser
2077 Leser
2072 Leser
2037 Leser